Skip to main
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is in a strong financial position as it remains the largest single provider for Blue Cross Blue Shield branded coverage in 14 states, with the potential to expand through acquisitions and penetration in government-sponsored programs. The company's unique position and broad diversification provide opportunities for growth, and its commitment to >12% EPS growth in 2027 reflects confidence in its long-term prospects. Valuation is attractive given the multiple expansion potential, and management's commitment to improving margins and achieving sustainable earnings growth through rate catch-ups, disciplined pricing, and M&A.

Bears say

Elevance Health is facing downside risks in their commercial market due to increasing pressure and potential adverse regulatory/legislative changes. The company's ability to control medical costs may also be hindered, and they may face challenges in growing their government pay and PBM businesses. This could result in a decrease in membership and a decrease in margins in the coming years. Additionally, the company's investments in AI/tech and scalability could also lead to a negative impact on earnings in the short term.

ELV has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 18 analysts, ELV has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $383.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $383.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.